ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 775

Endomyocardial Biopsies in the Diagnosis of Myocardial Involvement in Systemic Lupus Erythematosus

Laura Geraldino-Pardilla1, Teja Kapoor2, Thania Perez3 and Anca Askanase3, 1Division of Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, 2Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, 3Columbia University, College of Physicians & Surgeons, New York, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: biopsies, myocardial involvement and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Systemic Lupus Erythematosus – Clinical Poster I: Clinical Manifestations and Comorbidity

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Myocardial dysfunction is reported in over half of systemic lupus erythematosus (SLE) patients, yet the underlying pathogenesis remains poorly understood. Endomyocardial biopsies (EMBs) are considered the gold standard for diagnosing cardiac involvement and myocarditis in inflammatory conditions, including SLE. However, EMBs are rarely performed in clinical practice and most of the histopathology reports in the literature consist of post-mortem data. We sought to describe the histopathologic findings of EMBs in SLE patients with active cardiac symptoms.

Methods: A retrospective review of histopathology reports was performed on SLE patients at Columbia University Medical Center who underwent EMBs from 1994-2017. SLE patients were identified by ICD-9 & 10 codes. EMBs, performed for evaluation of unexplained low ejection fraction suspicious for myocarditis, were similarly identified by procedure codes for cardiac pathology. Out of 1,994 SLE patients identified by ICD codes, 59 had cardiac pathology reports. The diagnosis of SLE was confirmed in 41/59 patients by chart review using ≥ 4 revised 1997 ACR classification criteria or SLICC classification criteria. Eleven histopathology reports were EMBs and the remaining were valvular specimens. Demographics, SLE characteristics, and cardiovascular disease risk factors were ascertained by chart review.

Results: Data from eleven SLE EMBs patients was reviewed (Table 1). Mean age was 37 ± 17; 82% were female, and median disease duration was 2.5 years (0-25.5). Anti-dsDNA and anti-SSA/Ro antibodies were present in 64% and 45%, respectively. Forty-five percent had hypertension, 27% had coronary artery disease, 9% had hyperlipidemia, and 36% had end-stage renal disease; none had diabetes or smoked. One patient had antiphospholipid antibody syndrome on anticoagulation. Mean ejection fraction was 37%. On histopathology, 91% had mild interstitial fibrosis, 82% had myocyte hypertrophy, 27% had organized blood clots, and 27% had a mild infiltration of lymphocytes and macrophages without clear evidence of myocarditis. None of the patients had vasculitis, endocarditis, ischemia, or amyloid deposition. Glycogen storage was observed in one patient.

Conclusion: EMBs are rarely performed in SLE. Inflammatory infiltrates were present in only 27% of all SLE EMBs and non-specific interstitial fibrosis and myocyte hypertrophy were the most common findings. These data suggest that EMBs have limited value in the diagnosis of cardiac involvement in lupus and support the need for alternative diagnostic approaches to SLE heart disease.

Table 1. Patient Characteristics.

SLE EMBs (n=11)

Demographics

Age, years, mean ± SD

37 ± 17

Female, n (%)

9 (82)

Race/Ethnicity (n=7)

Non-Hispanic White, n (%)

0

Non-Hispanic Black, n (%)

2 (29)

Hispanic, n (%)

3 (43)

Asian, n (%)

2 (29)

SLE Characteristics

SLE duration, years, median (IQR)

2.5 (0-25.5)

Lupus nephritis, n (%)

5 (45)

End-stage renal disease, n (%)

4 (36)

Antiphospholipid syndrome, n (%)

1 (9)

ANA, n (%)

11 (100%)

ds-DNA, , n (%)

7 (64)

SSA/Ro, n (%)

5 (45)

SSB/La, n (%)

3 (27)

Sm, n (%)

5 (45)

RNP, n (%)

5 (45)

Anti-malarials, n (%)

4 (36)

Steroids, n (%)

4 (36)

Mycophenolate mofetil, n (%)

4 (36)

Azathioprine, n (%)

0

Methotrexate, n (%)

0

Cyclophosphamide, n (%)

0

B cell therapy, n (%)

0

Cardiovascular Risk Factors and Assessments

Smoking, n (%)

0

Hypertension, n (%)

5 (45)

Diabetes, n (%)

0

Hyperlipidemia, n (%)

1 (9)

Statin use, n (%)

3 (27)

Coronary artery disease, n (%)

3 (27)

Mean ejection fraction on echocardiogram, %

37%

Valvular abnormalities on echocardiogram, n (%)

3 (27)

Histopathology

Myocyte hypertrophy, n (%)

9 (82)

Mild interstitial fibrosis, n (%)

10 (91)

Myocardial inflammatory infiltration, n (%)

3 (27)

Organized blood clot, n (%)

3 (27)

Endocarditis, n (%)

0

Vasculitis, n (%)

0

Ischemia, n (%)

0

Amyloid deposition, n (%)

0

Glycogen storage, n (%)

1 (9)


Disclosure: L. Geraldino-Pardilla, None; T. Kapoor, None; T. Perez, None; A. Askanase, None.

To cite this abstract in AMA style:

Geraldino-Pardilla L, Kapoor T, Perez T, Askanase A. Endomyocardial Biopsies in the Diagnosis of Myocardial Involvement in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/endomyocardial-biopsies-in-the-diagnosis-of-myocardial-involvement-in-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/endomyocardial-biopsies-in-the-diagnosis-of-myocardial-involvement-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology